Chi-Chung Li

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Diffuse Large B Cell Lymphoma

Acute Lymphoblastic Leukemia

Top Venues

Clinical and translational science

Clinical pharmacology and therapeutics

CPT: pharmacometrics & systems pharmacology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Brendan Bender, Chi-Chung Li, Mathilde Marchand, David C Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Yan Jin, Chunze Li, Shen Yin, Michael Wei, Pascal Chanu
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical and translational science 17 (6) (2024)
Gerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, Nageshwar Budha, Ferdous Gheyas, Chi-Chung Li, Yuan Chen, Anne-Gaëlle Dosne, Niels Rode Kristensen, Mindy Magee, Mahesh N Samtani, Vikram Sinha, Kunal S Taskar, Vijay V Upreti, Jianning Yang, Jack Cook
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program. Clinical pharmacology and therapeutics 116 (2) (2024)
Gerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, Nageshwar Budha, Ferdous Gheyas, Chi-Chung Li, Yuan Chen, Anne-Gaëlle Dosne, Niels Rode Kristensen, Mindy Magee, Mahesh N Samtani, Vikram Sinha, Kunal S Taskar, Vijay V Upreti, Jianning Yang, Jack Cook
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program. Clinical pharmacology and therapeutics (2024)
Brendan Bender, Chi-Chung Li, Mathilde Marchand, David C Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Yan Jin, Chunze Li, Shen Yin, Michael Wei, Pascal Chanu
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical and translational science 17 (6) (2024)
Brendan Bender, Chi-Chung Li, Mathilde Marchand, David C Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Yan Jin, Chunze Li, Shen Yin, Michael Wei, Pascal Chanu
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical and translational science 17 (6) (2024)
Brendan Bender, Chi-Chung Li, Mathilde Marchand, David C Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Yan Jin, Chunze Li, Shen Yin, Michael Wei, Pascal Chanu
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical and translational science 17 (6) (2024)
Monica E Susilo, Chi-Chung Li, Kapil Gadkar, Genevive Hernandez, Ling-Yuh Huw, Jin Y Jin, Shen Yin, Michael C Wei, Saroja Ramanujan, Iraj Hosseini
Systems-based Digital Twins to Help Characterize Clinical Dose-Response and Propose Predictive Biomarkers in a Phase I Study of Bispecific Antibody, Mosunetuzumab, in NHL. Clinical and translational science (2023)
Yuan Chen, Fang Ma, Nicholas Jones, Rong Deng, Chunze Li, Chi-Chung Li
Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling. CPT: pharmacometrics & systems pharmacology (2023)
Monica E Susilo, Chi-Chung Li, Kapil Gadkar, Genevive Hernandez, Ling-Yuh Huw, Jin Y Jin, Shen Yin, Michael C Wei, Saroja Ramanujan, Iraj Hosseini
Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. Clinical and translational science (2023)
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, Stephen J Schuster, Chan Yoon Y Cheah, Matthew J Matasar, Gareth Peter Gregory, Dok-Hyun Yoon, Mazyar Shadman, Keith Fay, Sung Soo Yoon, Carlos Panizo, Ian W Flinn, Anna M Johnston, Francesc Bosch, Laurie H Sehn, Michael C Wei, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, L Elizabeth Elizabeth Budde
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood advances (2023)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C Piccione, Michael C Wei, Shen Yin, Nancy L Bartlett
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (5) (2021)